中国继续医学教育
中國繼續醫學教育
중국계속의학교육
China Continuing Medical Education
2015年
24期
144-145
,共2页
拉米夫定%阿德福韦酯%乙肝%肝硬化%失代偿%疗效
拉米伕定%阿德福韋酯%乙肝%肝硬化%失代償%療效
랍미부정%아덕복위지%을간%간경화%실대상%료효
Lamivudine%Adefovir dipivoxil%Hepatitis B%Cirrhosis%Loss compensation stage%Clinical effects
目的:探讨拉米夫定联合阿德福韦酯治疗乙肝肝硬化失代偿期临床疗效。方法研究对象选取我院2011年5月~2014年5月收治的乙肝肝硬化失代偿期患者40例,采用随机数字表法分为对照组(20例)和试验组(20例),分别给予阿德福韦酯口服和在此基础上加用拉米夫定口服治疗;比较两组患者治疗前后TBil、ALT及AST等肝功能相关指标水平,乙肝病毒DNA和乙肝e抗原转阴率等。结果试验组患者治疗后TBil、ALT及AST水平均优于对照组、治疗前(P<0.05);试验组患者乙肝病毒DNA和乙肝e抗原转阴率均高于对照组(P<0.05)。结论拉米夫定联合阿德福韦酯治疗乙肝肝硬化失代偿期可有效延缓肝脏功能损伤,促进乙肝病毒转阴。
目的:探討拉米伕定聯閤阿德福韋酯治療乙肝肝硬化失代償期臨床療效。方法研究對象選取我院2011年5月~2014年5月收治的乙肝肝硬化失代償期患者40例,採用隨機數字錶法分為對照組(20例)和試驗組(20例),分彆給予阿德福韋酯口服和在此基礎上加用拉米伕定口服治療;比較兩組患者治療前後TBil、ALT及AST等肝功能相關指標水平,乙肝病毒DNA和乙肝e抗原轉陰率等。結果試驗組患者治療後TBil、ALT及AST水平均優于對照組、治療前(P<0.05);試驗組患者乙肝病毒DNA和乙肝e抗原轉陰率均高于對照組(P<0.05)。結論拉米伕定聯閤阿德福韋酯治療乙肝肝硬化失代償期可有效延緩肝髒功能損傷,促進乙肝病毒轉陰。
목적:탐토랍미부정연합아덕복위지치료을간간경화실대상기림상료효。방법연구대상선취아원2011년5월~2014년5월수치적을간간경화실대상기환자40례,채용수궤수자표법분위대조조(20례)화시험조(20례),분별급여아덕복위지구복화재차기출상가용랍미부정구복치료;비교량조환자치료전후TBil、ALT급AST등간공능상관지표수평,을간병독DNA화을간e항원전음솔등。결과시험조환자치료후TBil、ALT급AST수평균우우대조조、치료전(P<0.05);시험조환자을간병독DNA화을간e항원전음솔균고우대조조(P<0.05)。결론랍미부정연합아덕복위지치료을간간경화실대상기가유효연완간장공능손상,촉진을간병독전음。
Objective To investigate clinical effects of lamivudine combined with adefovir dipivoxil in treatment of loss compensation stage of Hepatitis B cirrhosis. Methods 40 patients with loss compensation stage of Hepatitis B cirrhosis were chosen in the period from May 2011 to May 2014 and randomly divided into both group including control group (20 patients) with adefovir dipivoxil used alone and treatment group (20 patients) with lamivudine on the basis of control group, and the related indicators of liver function including TBil, ALT and AST before and after treatment, seroconversion rate of hepatitis B virus DNA and e antigen of hepatitis B of both groups were compared. Results The related indicators of liver function including TBil, ALT and AST after treatment of treatment group was signiifcantly better than control group and before treatment (P<0.05). The seroconversion rate of hepatitis B virus DNA and e antigen of hepatitis B of treatment group was signiifcantly better than control group (P<0.05). Conclusion Lamivudine combined with adefovir dipivoxil in treatment of loss compensation stage of Hepatitis B cirrhosis can efifciently delayed liver function damage and promote the clearance of hepatitis B virus.